Our team is pioneering urogenital healthcare with first-in-class, patent-pending therapeutics that target the microbiota–cancer axis and advancing prebiotic personal care, therapeutics, and medical devices.
Glyciome, LLC is a women-owned, Spokane-based, bioscience start-up commercializing first-in-class urogenital healthcare products. Our patent-pending therapeutics treat common genital infections and inflammation that contribute to genital cancers (such as those of the cervix, uterus, ovaries, prostate and penis). The formation and progression of these cancers are facilitated through a “microbiota-cancer axis” (i.e., the oncobiome), where harmful bacteria -and co-infections with viruses (such as herpes or HPV) - drive cancer-promoting genes and cell changes. Our founders have a unique understanding of genital ecosystem physiology which fosters development of breakthrough interventions with unparalleled efficacy and safety.
Glyciome is developing therapeutic drugs, medical devices, and personal care products that are changing genital care paradigms. Our products support healthy surface function across all ages. Common genital infections more than double the risk of developing genital cancers. Our patent portfolio combines cutting-edge science in metabolomics, nanotechnology, and human-centered design-thinking, to meet the demands of the $126B/yr. global personal and genital healthcare market.